Search results for "ANTHRACYCLINE"

showing 10 items of 92 documents

Implications du stress oxydant et du fer dans la cardiotoxicité des anthracyclines et du trastuzumab

2015

Cancer treatment has advanced considerably in recent years, allowing a reduction in mortality. Longer life expectancy of patients has helped to highlight the delayed onset of cardiovascular toxicity induced by these chemotherapies. The pathophysiological mechanisms responsible for these cardiac dysfunctions are complex, entangled and remain partially unknown. A better understanding of the phenomena involved in these cardiotoxicities is needed to prevent their occurrence. Therefore, we have developed two different experimental approaches to understand the pathophysiological mechanisms involved in the cardiac toxicity of anthracyclines and trastuzumab.A first experimental study aimed to clari…

Surpoids[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyStress oxydant[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyAnthracyclinesTrastuzumabCardiotoxicityCardiotoxicité[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCancer
researchProduct

Cardiotoxicity of cancer therapy

2011

Despite the development of new anti-cancer drugs such as anti-tyrosine kinases or anti-angiogenic therapy, cancer mortality remains high. These new molecules associated with advances in cancer surgery, radiotherapy and chemotherapy have succeeded in improving life expectancy in these patients. It has also allowed a long-term evaluation of the cardiovascular impact of these therapies. Many chemotherapy drugs, such as anthracyclines, lead to impaired cardiac function. The pathophysiological mechanisms of this cardiac dysfunction are complex, intricate and remain partially unknown. To reduce this cardiotoxicity, different pathways concerning administration modalities, drug presentation and the…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyStress oxydantOxidative stress[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyAnthracyclinesPronostic cardiovasculaire[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCardiotoxicityCardiotoxicitéCardiovascular prognosisCancer
researchProduct

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug …

2016

Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to th…

cardio-oncologymedicine.medical_treatmentCardiomyopathyheart failure030204 cardiovascular system & hematologyanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Anthracyclines; Antibiotics Antineoplastic; Cardiology; Cardiomyopathies; Cardiotoxicity; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Disease Managementanthracyclines; cardiotoxicity; heart failurecardiology consult0302 clinical medicineCardiologistsAntibioticsNeoplasmsDisease management (health)Societies Medicalmedia_commonanthracyclinesAntibiotics AntineoplasticDisease ManagementGeneral MedicineAntineoplasticItalyCardiovascular Diseases030220 oncology & carcinogenesisSupplement SubmissionPractice Guidelines as TopicCardiologyCardiomyopathiesRisk assessmentCardiology and Cardiovascular MedicineDrugmedicine.medical_specialtyAnthracyclinemedia_common.quotation_subjectCardiologycardiotoxicityanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Cardiology and Cardiovascular MedicineAntineoplastic AgentsanthracyclineRisk Assessment03 medical and health sciencesMedicalInternal medicinemedicineHumansIntensive care medicineCardiotoxicityChemotherapybusiness.industrymedicine.diseaseHeart failureSocietiesbusinessJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Oxidative Stress and Cognitive Alterations Induced by Cancer Chemotherapy Drugs: A Scoping Review

2021

Cognitive impairment is one of the most deleterious effects of chemotherapy treatment in cancer patients, and this problem sometimes remains even after chemotherapy ends. Common classes of chemotherapy-based regimens such as anthracyclines, taxanes, and platinum derivatives can induce both oxidative stress in the blood and in the brain, and these effects can be reproduced in neuronal and glia cell cultures. In rodent models, both the acute and repeated administration of doxorubicin or adriamycin (anthracyclines) or cisplatin impairs cognitive functions, as shown by their diminished performance in different learning and memory behavioural tasks. Administration of compounds with strong antiox…

cognition0301 basic medicineAntioxidantPhysiologymedicine.medical_treatmentClinical BiochemistryReviewRM1-950Pharmacologymedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedicine<i>N-</i>acetylcysteineDoxorubicinplatinumCaffeic acid phenethyl esterMolecular BiologyMesnaanthracyclinesCisplatinChemotherapybusiness.industryCancerclinical trialCell Biologymedicine.diseaseN-acetylcysteinetaxanes030104 developmental biologychemistry030220 oncology & carcinogenesisbiomarkerTherapeutics. PharmacologybusinessOxidative stressmedicine.drugAntioxidants
researchProduct

Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women

2021

Purpose: It is well known that anticancer drugs used for treating breast cancer can cause cardiac toxicity, and less is known about vascular toxicity. The aim of this study was to assess subclinical vascular effects of anthracyclines and trastuzumab (TRZ) in women treated for breast cancer.Methods: We enrolled 133 female patients with breast cancer undergoing adjuvant treatment with anthracycline-containing chemotherapy (CT) followed by taxane (paclitaxel/docetaxel) + TRZ. Patients underwent a standard echocardiography including measurement of left ventricular ejection fraction and global longitudinal strain at baseline and at follow-up. Vascular toxicity was evaluated by measuring brachial…

medicine.medical_specialtyAnthracyclinePhysiologypulse wave velocitycardiotoxicity030204 cardiovascular system & hematologychemotherapy03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinePhysiology (medical)medicineQP1-981Pulse wave velocityvascular injuryOriginal ResearchTaxaneEjection fractionbusiness.industrymedicine.diseaseArterial stiffneBlood pressurearterial stiffness; cardiotoxicity; chemotherapy; pulse wave velocity; vascular injuryarterial stiffnessDocetaxel030220 oncology & carcinogenesisCardiologyArterial stiffnessbusinessmedicine.drugFrontiers in Physiology
researchProduct

Anthrazyklin-induzierte Kardiotoxizität: MRT des Herzens bei Kindern und Jugendlichen mit malignen Erkrankungen

2004

Purpose: Quantification of left and right ventricular function using MRI in young cancer patients treated with cardiotoxic anthracyclines. Materials and Methods: Twenty-eight patients (mean age 16.4 years) underwent cardiac MRI at 1.5 T. The study protocol consisted of morphologic T2-weighted images with fat suppression and cine steady-state free precession sequences (SSFP) for functional analysis. Seven patients were examined at the end of chemotherapy, two of them also repeatedly during therapy, and 21 patients following an average period of three years after finishing chemotherapy (range one month - 20 years) Results: The end-systolic volume index increased and the ejection fraction of t…

medicine.medical_specialtyCardiotoxicityChemotherapyEjection fractionAnthracyclinebusiness.industrymedicine.medical_treatmentCardiomyopathyCancerSteady-state free precession imagingmedicine.diseaseSurgerymedicine.anatomical_structureVentricleInternal medicinemedicineCardiologyRadiology Nuclear Medicine and imagingbusinessRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive …

2004

Abstract Background: Pixantrone (BBR 2778) is a novel aza-anthracenedione with superior activity compared to doxorubicin and mitoxantrone in various tumor models including hematological malignancies. Pixantrone single agent therapy led to major responses in patients (pts) with aggressive lymphoma including diffuse large B-cell lymphoma (DLCL). The safety of a CHOP-like regimen with pixantrone replacing doxorubicin (CPOP) was assessed in a dose-ranging study indicating a recommended dose of 150 mg/m² for pixantrone. Method: In this phase II study the primary objective was to assess the efficacy of the CPOP regimen (cyclophosphamide 750 mg/m² d1, pixantrone 150mg/m² d1, vincristine 1.4mg/m² d…

medicine.medical_specialtyMitoxantronePixantroneAnthracyclinebusiness.industryImmunologyFollicular lymphomaAggressive lymphomaCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologySurgeryNon-Hodgkin's lymphomachemistry.chemical_compoundchemistryInternal medicinemedicineMantle cell lymphomabusinessFebrile neutropeniamedicine.drugBlood
researchProduct

Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-…

2006

Abstract Background: Pixantrone is a novel aza-anthracenedione with less cardiotoxicity and superior activity compared to doxorubicin and mitoxantrone in murine leukemia and lymphoma tumor models. Pixantrone as single agent therapy led to major responses in patients (pts) with multiply relapsed aggressive non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLCL). In a phase I dose-ranging study of pixantrone (80 to 180 mg/m2) replacing doxorubicin (CPOP) in a CHOP-like regimen, the optimal dose (RD) from that study was found to be 150 mg/m2. Methods: In this international, multi-center, phase II study the primary objective was to assess the efficacy and safety of the CPOP…

medicine.medical_specialtyPixantroneAnthracyclinebusiness.industryImmunologyFollicular lymphomaCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyNon-Hodgkin's lymphomaSurgerychemistry.chemical_compoundInternational Prognostic Indexchemistryhemic and lymphatic diseasesInternal medicineMedicineMantle cell lymphomabusinessDiffuse large B-cell lymphomaFebrile neutropeniaBlood
researchProduct

Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.

2014

The anticancer efficacy of anthracyclines is limited by cumulative dose-dependent early and delayed cardiotoxicity resulting in congestive heart failure. Mechanisms responsible for anthracycline-induced heart damage are controversially discussed and effective preventive measures are preferable. Here, we analyzed the influence of the lipid lowering drug lovastatin on anthracycline-induced late cardiotoxicity three month after treatment of C57BL/6 mice with five low doses of doxorubicin (5×3mg/kg BW; i.p.). Doxorubicin increased the cardiac mRNA levels of BNP, IL-6 and CTGF, while the expression of ANP remained unchanged. Lovastatin counteracted these persisting cardiac stress responses evoke…

medicine.medical_specialtyStatinCardiotonic AgentsAnthracyclinemedicine.drug_classBiologymedicine.disease_causeDNA MitochondrialInternal medicineNatriuretic Peptide Brainpolycyclic compoundsmedicineAnimalsDoxorubicinHSP70 Heat-Shock ProteinsLovastatinPharmacologyCardiotoxicityEjection fractionAntibiotics AntineoplasticInterleukin-6Gene Expression ProfilingMyocardiumConnective Tissue Growth Factormedicine.diseaseFibrosisCardiotoxicityMice Inbred C57BLEndocrinologyDoxorubicinHeart failureFemaleLovastatinOxidative stressmedicine.drugDNA DamagePharmacological research
researchProduct

Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardio…

2021

Abstract Aims In breast cancer (BC) patients treated with anthracyclines-based therapies, we aim at assessing whether adjuvant drugs impact cardiac function differently and whether their cardiotoxicity has a regional pattern. Methods and results In a multicentre study, 146 BC patients (56 ± 11 years) were prospectively enrolled and divided into three groups according to the received treatments: AC/EC-Group (doxorubicin or epirubicin + cyclophosphamide), AC/EC/Tax-Group (AC/EC + taxanes), FEC/Tax-Group (fluorouracil + EC + taxanes). Fifty-six patients of the total cohort also received trastuzumab. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were calculated …

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiologyBreast NeoplasmsAnthracyclineAnthracyclines; Breast cancer; Cardiotoxicity; Myocardial strain030204 cardiovascular system & hematologyAnthracyclines Breast cancer Breast Neoplasms Cardiology Cardiotoxicity Echocardiography Female Humans italy Myocardial strain Pharmaceutical Preparations Stroke Volume Trastuzumab Ventricular Function Left Ventricular Dysfunction LeftVentricular Function LeftVentricular Dysfunction Left03 medical and health sciencesBreast cancer0302 clinical medicineTrastuzumabInternal medicineHumansMedicineAnthracyclinesRadiology Nuclear Medicine and imagingeducationeducation.field_of_studyChemotherapyCardiotoxicityEjection fractionbusiness.industryStroke VolumeGeneral MedicineTrastuzumabMyocardial strainChemotherapy regimenCardiotoxicityItalyPharmaceutical PreparationsEchocardiographyFluorouracil030220 oncology & carcinogenesisCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEpirubicinEuropean Heart Journal - Cardiovascular Imaging
researchProduct